Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Congenital Adrenal Hyperplasia (CAH), Familial Male-Limited Precocious Puberty (FMPP)
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Day to 99 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Continuous Versus Cyclical OCP Use in PCOS

NCT03819140
Conditions
Polycystic Ovary Syndrome
Interventions
Yasmin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Conditions
Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
Interventions
Spironolactone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Polycystic Ovary Syndrome
Interventions
Salsalate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Leuprolide
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Polycystic Ovary Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Research Triangle Park, North Carolina • Richmond, Virginia
Conditions
Adrenal Insufficiency, Excess Androgen, Congenital Adrenal Hyperplasia (CAH)
Interventions
Hydrocortisone (Solucortef), Insulin pump (Medtronic)
Drug · Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Polycystic Ovary Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Polycystic Ovary Syndrome, Hyperandrogenism
Interventions
Flutamide, Progesterone, estrace
Drug
Lead sponsor
University of Virginia
Other
Eligibility
13 Years to 17 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Polycystic Ovary Syndrome, Puberty Disorders, Ovulation Disorder
Interventions
Spironolactone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
13 Years to 19 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Polycystic Ovary Syndrome
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Springfield, Missouri • Philadelphia, Pennsylvania
Conditions
Congenital Portosystemic Shunt, CPSS (Congenital Portosystemic Shunt)
Interventions
Shunt Closure
Procedure
Lead sponsor
Prof. Valérie Mc Lin
Other
Eligibility
1 Day and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Chicago, Illinois
Conditions
Polycystic Ovary Syndrome, Anovulation, Hyperandrogenism, Insulin Resistance, Glucose Intolerance, Metabolic Complication
Interventions
Placebo, Inositol
Other · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Conditions
Polycystic Ovary Syndrome
Interventions
Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, Combination of treatments
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Conditions
Puberty, Hyperandrogenism
Interventions
Micronized progesterone suspension, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Hyperandrogenemia and Altered Day-night LH Pulse Patterns

NCT03068910
Conditions
Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
Interventions
Micronized progesterone, Spironolactone, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Polycystic Ovary Syndrome, Hyperandrogenism
Interventions
Metformin, Progesterone, estrace
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Hydrocortisone, dexamethasone, Cosyntropin, rhCG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 16 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women

NCT01889199
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
Flutamide, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Polycystic Ovary Syndrome, Hyperandrogenism, Normal Puberty
Interventions
Progesterone, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
Interventions
Metformin
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Hydrocortisone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Polycystic Ovary Syndrome
Interventions
3 mg DRSP/20 μg EE
Drug
Lead sponsor
Woman's
Other
Eligibility
16 Years to 35 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Polycystic Ovary Syndrome, Anovulation, Oligoovulation, Infertility, Hyperandrogenism
Interventions
Metformin, Clomiphene citrate, Placebo
Drug
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2003
U.S. locations
1
States / cities
Lackland Air Force Base, Texas